Business Wire

Cornèr Bank Group Completes Migration of 2.1m Cards to Vestigo’s Card Management Solution

1.7.2021 10:00:00 EEST | Business Wire | Press release

Share

Cornèr Bank Group, issuer of credit and prepaid cards to private individuals and businesses in Europe, has reached a major milestone in its digital transformation journey by completing migration of its card portfolios across all products and markets to a modern, consolidated solution. Vestigo is a European software provider in cards and account-to-account payments space, and its card management system (CMS) is the key component of the overall solution at Cornèr.

Cornèr Bank Group issues more than /2.1/ million credit and prepaid, Visa, Mastercard and Diners cards directly and through partnerships with hundreds of organizations of various sizes in a B2B2C / co-brand business model. The new solution, managed in-house on a single instance, will further improve innovation and quality of service to Cornèr Bank Group’s partners and ultimate cardholders, as well as enhance internal efficiency. Vestigo’s integrated, modular, “multi-everything” solution is fully customer centric, can manage all types of cards, as well as account-to-account payments, and allows for easy integration leveraging 200+ APIs.

This large-scale implementation and migration project was designed to minimize risk and consisted of multiple phases taking into account requirements regarding different markets, products and legacy systems.

Ing. Vittorio Cornaro, Chief Executive Officer of Cornèr Bank Group, said: “Partnering with a trusted partner like Vestigo helps us modernize and consolidate our pan-European card business, which is the key step of our strategy to transform Cornèr into an agile bank delighting our clients and partners every day with best-in-class products and services”

Simone Tettamanti, CIO at Cornèr Banca, added: This complex, large-scale project was an excellent example of two organizations working together successfully as trusted partners towards a common goal, using agile approach. This modern platform will facilitate Cornèr’s business growth and provide us with flexibility to adjust to evolving customer requirements in the future.”

Kata Kamenski, Chief Executive Officer and Co-founder of Vestigo said: “We’re incredibly proud to work with Cornèr, as this further validates Vestigo’s functionality fit, as well as delivery ability fit with sophisticated, innovative financial institutions. Vestigo continues growing strongly, driven by its differentiating capability to drive convergence across cards and account-to-account payments. Our solution is scalable and can be deployed as on-prem, cloud installation or SaaS.”

About Cornèr Bank Group

Founded in Lugano in 1952, the Cornèr Bank Group is an independent Swiss private bank group operating as a full-service bank. Lugano is Switzerland’s third-largest banking centre, after Zurich and Geneva. Active across the whole range of traditional banking services, the Cornèr Bank Group specializes in the private banking sector, as well as in the areas of lending, Visa, Mastercard and Diners Club payment cards (Cornèrcard) and online trading (Cornèrtrader) – the core businesses on which the growth of the Cornèr Bank Group is based. The Cornèr Bank Group comprises the Lugano-based parent bank Cornèr Bank Ltd., the four branches in Chiasso, Geneva, Locarno and Zurich, the branch BonusCard and the affiliates Cornèr Bank (Overseas) Limited, Cornèrcard UK Ltd., Cornèr Europe AG, Diners Club Italia S.r.l. and Dinit d.o.o.

For more information on Cornèr please visit: www.cornergroup.ch

About Vestigo

Vestigo is a founder-owned paytech, fully focused on cards (CMS) and account-to-account payments (PaymentsHub) space. Vestigo’s newest module HolisticPay is a rich payments modernization & convergence layer designed to facilitate managed cards & payments modernization. Our continuously increasing team has more than 130 employees. Vestigo’s modern, modular, customer-centric solution creates value for financial institution clients in payments, issuing and acquiring businesses. We differentiate by bringing the cards and account payments together in a fully customer centric way using modern technology. Vestigo currently supports clients in 7 European countries, with a strong growth strategy into further markets.

For more information on Vestigo please visit: www.vestigo.hr

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cornèr Media Contact
Anna Russo, Head of PR
T +41 91 800 53 54
E anna.russo@corner.ch

Vestigo Media Contact:
Valbona Guscic
T +385 91 6392902
E valbona.guscic@vestigo.hr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye